7 completed, 5 terminated, 3 active not recruiting, 3 withdrawn. 20 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 7, Terminated 5, Active not recruiting 3, Withdrawn 3, Recruiting 2 |
| Phase 1 | 6 | Terminated 3, Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow ECG: new trials by email Literature Review of ECG trials Research Report on ECG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride - Malignant Digestive System Neoplasm | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 60 | 2026-04-30 | 2026-06-02 |
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma Onvansertib, Gemcitabine, Nab-paclitaxel - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2024-08-01 | 2024-07-19 | |
| Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies MGCND00EP1, Placebo, ECG - Resistant Epilepsy, Drug, Adolescent Epilepsy | Phase 2 | Withdrawn | MGC Pharmaceuticals d.o.o | 2024-05-30 | 2024-06-03 | |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma Olaparib, ECG, CT CAP - Pancreatic Acinar Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2023-12-14 | 2026-08-14 |
| A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction Low calorie meal replacement plan, Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy, Transthoracic echocardiography - Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic | Phase 2 / Phase 3 | Completed | University of Leicester | 66 | 2023-12-05 | 2026-07-22 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| BMS-986253 in Myelodysplastic Syndromes Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2022-11-29 | 2025-09-30 |
| Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis Paclitaxel, Nilotinib, ECG - Gynecologic Cancer, Gynecologic Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2022-10-13 | 2026-06-25 |
| Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 Biochemistry blood test, Hematology blood test, D-Dimer test (coagulation) - Covid19, Corona Virus Infection | Phase 2 | Completed | MGC Pharmaceuticals d.o.o | 240 | 2022-10-11 | 2023-03-15 |
| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes Dilanubicel, Cyclophosphamide, Fludarabine - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 31 | 2022-05-10 | 2026-07-10 |
| Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) Minnelide, ECG, CT/MRI - Adenosquamous Carcinoma of the Pancreas | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2022-03-07 | 2026-08-14 |
| Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19 Covidir injections, Quantitative PCR SARS-CoV-2, IgM and IgG dosage - COVID-19 | Phase 2 | Recruiting | Code Pharma | 130 | 2022-01-20 | 2024-10-02 |
| Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease Ibrutinib, ECG, PFT's - Chronic GVHD | Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2021-05-10 | 2026-01-23 |
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2021-04-28 | 2024-08-27 |
| Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy - Follicular Lymphoma, Non-Hodgkin's Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2019-08-22 | 2026-03-03 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer EP0057, olaparib, CT scan - Urothelial Carcinoma, Urothelial Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 45 | 2016-05-09 | 2026-08-13 |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Rituximab, Conditioning chemotherapy, TMS - Myelodysplastic Syndromes, Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 34 | 2015-09-24 | 2025-09-30 |
| ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure ZP120, I.v. catherization, 6-minutes walk performance - Heart Failure, Congestive | Phase 2 | Terminated | Zealand Pharma | 130 | 2006-01-01 | 2007-02-28 |
Myelodysplastic Syndromes (5) · Hematologic Neoplasms (3) · COVID-19 (2) · Leukemia (2) · Leukemia, Biphenotypic, Acute (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Appendiceal Neoplasms (1) · Bone Marrow Diseases (1) · Breast Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Transitional Cell (1)
National Cancer Institute (NCI) (10) · MGC Pharmaceuticals d.o.o (2) · Children's Oncology Group (1) · Code Pharma (1) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · Thomas Jefferson University (1) · University of Leicester (1) · Zealand Pharma (1)
United States (15) · Israel (2) · Brazil (1) · Canada (1) · Slovenia (1) · United Kingdom (1)
Chen Zhao, M.D. (2) · Najla El Jurdi, M.D. (2) · Alain Mina, M.D. (1) · Andrew M Blakely, M.D. (1) · Anish Thomas, M.D. (1) · Charles D Lopez (1) · Chetan Jeurkar, DO (1) · Filippo Milano (1) · Gerry P McCann, MD (1) · James Gulley, M.D. (1) · Joerg Herrmann, MD (1) · Kelly E Faulk (1) · Rahul Lakhotia, M.B.B.S. (1) · Rita Nadaf (1) · Rubi Zomer (1)
PMID 32897402, PMID 35535581, PMID 39880434, PMID 40331908, PMID 42820295
P30CA015704 (1), P50HL110787 (1), U10CA180886 (1)